Henlius  celebrated its World R&D Day 2025, under the theme "Collaborate to Create", bringing together senior executives, experts and industry leaders to discuss advances in R+D, strategic planning and cutting-edge therapies. The event attracted hundreds of participants from academia, industry and the investment sector.

Henlius introduced its strong portfolio of innovative products, including serplulimab (anti-PD-1 mAb), HLX22 (anti-HER2 mAb) and HLX43 (PD-L1 ADC), which seek to address unmet needs in lung and gastrointestinal cancers. HLX43, China's first PD-L1 ADC and the world's second-largest, combines a proprietary antibody with MediLink's dual-release payload, demonstrating promising preclinical efficacy and good safety profiles. Meanwhile, HLX22 targets HER2-positive gastric cancer with a novel mechanism to block tumor signaling pathways, positioning it as a potential first-line therapy for the treatment of HER2-positive CG, as well as a potential treatment option in patients with HER2-positive cancers.

In addition to its innovative product line and portfolio, the company highlighted its three innovative technology platforms: Hinova TCE (Trispecific T-Cell Activator) Platform for Solid Tumors, ADC's proprietary Hanjugator™ platform, and AI-based drug discovery platform HAI Club. These platforms have formed a collaborative R+D matrix to accelerate the development of differentiated therapies. Meanwhile, Henlius is strategically driving the development of its Henozye™ hyaluronidase and subcutaneous injection technologies, accelerating formulations of new drugs and biosimilars, while extending the shelf life of products.

Globalization remains a key objective for Henlius, and Japan has been prioritized as a strategic market in its "Internationalization 2.0" strategy. Henlius is taking advantage of the aging Japanese population and regulatory environment to boost clinical trials of HLX22 and serplulimab (anti-PD-1), with the aim of building an end-to-end value chain, from R+D to commercialization. In the "Partnership for Success" panel, 2022 Nobel Laureate Prof. Carolyn Bertozzi highlighted the promise of sialoglycan-targeted therapies in oncology and immunology. Thanks to the collaboration with Henlius, the development of the human sialidase fusion protein HLX79 (E-602) has been accelerated. Industry leaders highlighted Henlius' integrated capabilities in antibody development, clinical execution and global quality manufacturing as key factors in forging high-impact partnerships. Driven by trust-based partnerships, the company expands its therapeutic ecosystem globally.

The event concluded with a call for industry-wide collaboration to bridge the gap between preclinical and clinical processes, leveraging AI and data-driven strategies to accelerate patient-centric innovation. By 2025, Henlius aims to transform technological advancements into clinical value, reinforcing China's role in the global biopharmaceutical industry.